Arthur T. Sands
2022 - Nurix Therapeutics
In 2022, Arthur T. Sands earned a total compensation of $9.4M as President, Chief Executive Officer and Director at Nurix Therapeutics, a 97% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $293,250 |
|---|---|
| Option Awards | $8,505,239 |
| Salary | $572,083 |
| Other | $45,649 |
| Total | $9,416,222 |
Sands received $8.5M in option awards, accounting for 90% of the total pay in 2022.
Sands also received $293.3K in non-equity incentive plan, $572.1K in salary and $45.6K in other compensation.
Rankings
In 2022, Arthur T. Sands' compensation ranked 283rd out of 5,501 executives tracked by ExecPay. In other words, Sands earned more than 94.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 283 out of 5,501 | 95th |
Division Manufacturing | 116 out of 2,980 | 96th |
Major group Chemicals And Allied Products | 28 out of 1,335 | 98th |
Industry group Drugs | 20 out of 1,238 | 98th |
Industry Pharmaceutical Preparations | 16 out of 892 | 98th |
Source: SEC filing on March 24, 2023.
Sands' colleagues
We found two more compensation records of executives who worked with Arthur T. Sands at Nurix Therapeutics in 2022.
News
Nurix Therapeutics CEO Arthur Sands' 2023 pay falls 54% to $4.4M
March 27, 2024
Nurix Therapeutics CEO Arthur Sands' 2022 pay jumps 97% to $9.4M
March 24, 2023
Nurix Therapeutics COO Stefani Wolff receives $7.1M in 2021
March 25, 2022
Nurix Therapeutics CEO Arthur Sands' 2020 pay jumps 1,041% to $17M
March 25, 2021